Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cardiol Therapeutics (NQ: CRDL ) 1.970 +0.020 (+1.03%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 122,322 Open 1.940 Bid (Size) 1.930 (1) Ask (Size) 2.040 (14) Prev. Close 1.950 Today's Range 1.940 - 2.010 52wk Range 0.6610 - 3.120 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News “Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…” September 12, 2024 Via AB Newswire CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024 August 12, 2024 CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Performance YTD +123.86% +123.86% 1 Month +2.07% +2.07% 3 Month -0.51% -0.51% 6 Month +3.68% +3.68% 1 Year +152.24% +152.24% More News Read More Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients June 17, 2024 Via TheNewswire.com Exposures Product Safety Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients June 17, 2024 Via News Direct Exposures Product Safety Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis June 13, 2024 Via Newsfile Sector Spotlight: Orphan Drug Developers With Significant Upside June 03, 2024 Via AB Newswire Topics ETFs Exposures Product Safety Sector Spotlight: Orphan Drug Developers With Significant Upside June 03, 2024 Via TheNewswire.com Topics ETFs Exposures Product Safety Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) May 28, 2024 Via AB Newswire Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics May 28, 2024 Via News Direct CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024 May 14, 2024 Via InvestorPlace Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In May 14, 2024 Via Benzinga Topics Cannabis Exposures Cannabis CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023 April 02, 2024 Via InvestorPlace Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis February 21, 2024 Via Newsfile Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis February 15, 2024 Via Newsfile Exposures Product Safety Cardiol Therapeutics - This Penny Stock Is An Analysts Favorite January 31, 2024 Via Talk Markets Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis November 01, 2023 Via Newsfile Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 Via Get News Topics Death Exposures Death Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 Via News Direct Topics Death Exposures Death Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases October 13, 2023 Via TheNewswire.com Topics Death Exposures Death Cardiol Therapeutics Fights Heart Inflammation With Novel Formulations October 12, 2023 Via Benzinga CBD To Treat Heart Failure? New Study Shows Its Cardioprotective Effects October 10, 2023 Via Benzinga Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction October 10, 2023 Via Newsfile Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket September 21, 2023 Via Benzinga Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis September 19, 2023 Via Newsfile Sidoti's Micro-Cap Virtual May Conference May 09, 2023 Via ACCESSWIRE Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
